Patterns of mutations in TP53 mutated AML

John S. Welch

Research output: Contribution to journalReview articlepeer-review

33 Scopus citations


TP53 mutated acute myeloid leukemia (AML) responds poorly to chemotherapy and has a short overall survival rate with a median of 5–9 months. Poor outcomes in TP53 mutated AML following chemotherapy have been observed and treatment options remain limited, although the presence of TP53 mutations alone should not be a barrier to therapy. Decitabine is emerging as an alternative treatment option for patients with TP53 mutated AML, although the agent has not been associated with deep molecular remissions and requires additional consolidation. The clinical and genomic characteristics of TP53 mutated AML are reviewed in this paper.

Original languageEnglish
Pages (from-to)379-383
Number of pages5
JournalBest Practice and Research: Clinical Haematology
Issue number4
StatePublished - Dec 2018


  • AML
  • Acute myeloid leukemia
  • CHIP
  • Clonal hematopoiesis of indeterminate potential
  • Decitabine
  • MDS
  • Mutation patterns
  • Myelodysplastic syndromes
  • TP53


Dive into the research topics of 'Patterns of mutations in TP53 mutated AML'. Together they form a unique fingerprint.

Cite this